CLINICAL EFFECT OF HEMABATE IN PREVENTING AND TREATING POSTPARTUM HEMORRHAGE CAUSED BY UTERINE INERTIA.

Objective: To analyze the clinical effect of Hemabate in preventing and treating postpartum hemorrhage caused by uterine inertia.Methods: 80 cases of parturient women with high-risk factors of uterine inertia who delivered in our hospital between January 2017 and July 2018 were selected as subjects. With the approval of the ethics committee, parturient were divided into observation group (case number =40) and control group (case number =40) based on the random principle. In the observation group, Hemabate was given to prevent and treat postpartum hemorrhage, while in the control group, oxytocin was given to prevent and treat postpartum hemorrhage.Result: Compared with the control group, the incidence of postpartum hemorrhage in the observation group (7.5%) was significantly lower than that in the control group (20.0%), and the difference was statistically significant (P<0.05). The blood loss at 2h and 24h postpartum was significantly lower in the observation group than in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions, such as vomiting, hypothermia, headache and elevated blood pressure, was significantly lower in the observation group (7.5%) than in the control group (27.5%), and the difference was statistically significant (P<0.05).Conclusion: The application of Hemabate in the prevention and treatment of postpartum hemorrhage caused by uterine inertia can significantly reduce the incidence of postpartum hemorrhage, reduce the amount of postpartum hemorrhage, with low adverse reactions and higher drug safety.